MKI67 and neoplasm: On the contrary, a small pre-clinical trial of early-stage NSCLC patients described that Ki-67 expression correlates with increased immune checkpoint expression on both tumour and TILs within the TME [111], advocating that evaluating pre-treatment Ki-67 levels may present predictive value for those indicated to undergo combined cytotoxic chemotherapy, ICI, or novel combinations.